Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Cytochrome P450 3A4 Inducers [MoA]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
ENZALUTAMIDE 49,270 9,676 19.6% 9,282 576 76.0 yrs 0.6%
TOPIRAMATE 28,609 3,527 12.3% 7,098 2,263 38.4 yrs 74.5%
OSIMERTINIB 27,750 12,456 44.9% 5,277 757 68.2 yrs 66.0%
CARBAMAZEPINE 24,577 2,156 8.8% 9,608 1,705 50.1 yrs 61.8%
DABRAFENIB 19,305 4,165 21.6% 5,325 500 58.3 yrs 48.0%
DEFERASIROX 11,322 2,661 23.5% 4,008 357 49.8 yrs 50.1%
CLOBAZAM 10,596 725 6.8% 3,312 553 29.3 yrs 49.1%
CENOBAMATE 5,643 125 2.2% 1,012 94 38.2 yrs 56.4%
APREPITANT 5,620 1,195 21.3% 2,917 1,170 52.8 yrs 70.9%
ESLICARBAZEPINE 3,127 97 3.1% 750 145 42.8 yrs 56.8%

Head-to-Head Comparisons

ENZALUTAMIDE vs TOPIRAMATE ENZALUTAMIDE vs OSIMERTINIB ENZALUTAMIDE vs CARBAMAZEPINE ENZALUTAMIDE vs DABRAFENIB TOPIRAMATE vs OSIMERTINIB TOPIRAMATE vs CARBAMAZEPINE TOPIRAMATE vs DABRAFENIB OSIMERTINIB vs CARBAMAZEPINE OSIMERTINIB vs DABRAFENIB CARBAMAZEPINE vs DABRAFENIB
← Back to Cytochrome P450 3A4 Inducers [MoA] Class side effects →